NEW YORK, Dec. 17, 2023 (GLOBE NEWSWIRE) -- Lowey Dannenberg P.C., a preeminent law firm in obtaining redress for consumers and investors, is investigating the proposed all-stock merger between Standard BioTools Inc. (“Standard BioTools”) (NASDAQ: LAB) and SomaLogic, Inc. (“SomaLogic”) (NASDAQ: SLGC).
On October 4, 2023, Standard BioTools and SomaLogic announced a merger whereby, under the terms of the agreement, SomaLogic shareholders will receive 1.11 shares of Standard BioTools common stock for each share of SomaLogic common stock owned. Upon the close of the transaction, Standard BioTools shareholders will own approximately 43% of the combined company, and SomaLogic shareholders will own approximately 57% of the combined company on a fully diluted basis. The merger is expected to close in early 2024.
This investigation seeks to determine whether SomaLogic shareholders are receiving adequate consideration and process.
If you are a SomaLogic shareholder, and wish to participate, learn more, or discuss the issues surrounding the investigation, please contact attorneys at (914) 733-7256 or via email to Andrea Farah (afarah@lowey.com) or Vincent R. Cappucci Jr. (vcappucci@lowey.com).
About Lowey Dannenberg
Lowey Dannenberg is a national firm representing institutional and individual investors, who suffered financial losses resulting from corporate fraud and malfeasance in violation of federal securities and antitrust laws. The firm has significant experience in prosecuting multi-million-dollar lawsuits and has previously recovered billions of dollars on behalf of investors.
Contact
Lowey Dannenberg P.C.
44 South Broadway, Suite 1100
White Plains, NY 10601
Tel: (914) 733-7256
Email: investigations@lowey.com
SOURCE: Lowey Dannenberg
